Are all antidepressants the same?

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 6, 2000, Pages 24-28

  Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUROTOXICITY; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS; AROUSAL; COGNITION; DEPRESSIVE DISORDER; EMOTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, PSYCHOLOGICAL; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, SEROTONIN; SEVERITY OF ILLNESS INDEX; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 0342699642     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Kessler RC, McGonagle KA, Zhao S. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
2. Coyne JC, Kessler RC, Tal M, et al. Living with a depressed person. J Consult Clin Psychol 1987;55:347-352
3. Mintz J, Mintz LL, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
4. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850-856
5. Koenig HG, Kuchibhatla M. Use of health services by hospitalized medically ill depressed elderly patients. Am J Psychiatry 1998;155:871-877
6. Deakin JFW. Does selectivity matter? Int Clin Psychopharmacol 1996;11 (suppl 1):13-17
7. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16(3):1S-9S
8. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55(12, suppl):3-15
9. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997:11(suppl):S25-S31
10. Carlsson A, Corrodi H, Fuxe K, et al. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur J Pharmacol 1969;5:357-366
11. Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(suppl 6):4-6
12. Healy D. The case for an individual approach to the treatment of depression. J Clin Psychiatry 2000;61 (suppl 6):18-23
13. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
14. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998;13(suppl 1):S29-S39
15. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11 (4, suppl):S9-S15
16. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249
17. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997;17:19S-28S
18. Clerc GE, Ruimy P. Verdeau-Paillès J, et al. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:138-143
19. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996; 11:41-46
20. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-312
21. Montgomery SA. Managing the severely ill and long-term depressed. Int J Psychiatry Clin Pract 1999;3(suppl 1):S13-S17
22. Massana J, Möller H-J, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80
23. Paykel ES. Social functioning and the depressed patient. Int J Psychiatry Clin Pract 1999;3(suppl 1):S9-S11
24. Kocsis JH, Frances AJ, Voss C, et al. Imipramine and social-vocational adjustment in chronic depression. Am J Psychiatry 1988;145:997-999
25. Friedman RA, Markowitz JC, Parides M, et al. Acute response of social functioning in dysthymic patients with desipramine. J Affect Disord 1995; 34:85-88
26. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619
27. Heiligenstein JH, Ware JE, Beusterien KM, et al. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr 1995;7:125-137
28. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale. Eur Neuropsychopharmacol 1997;7(suppl 1):S57-S70
29. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997; 7(suppl 1):S49-S55
30. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11(4, suppl):S17-S23